10-Q: Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Tenax Therapeutics reports increased research and development spending as it advances its Phase 3 clinical program for levosimendan, while also securing significant funding through a private placement.

Summary

• Tenax Therapeutics reported a net loss of $3.58 million for the three months ended June 30, 2024, and $7.37 million for the six months ended June 30, 2024.
• The company's research and development expenses significantly increased to $2.33 million for the three months and $5.0 million for the six months ended June 30, 2024, primarily due to the advancement of the Phase 3 LEVEL trial for oral levosimendan.
• General and administrative expenses were $1.34 million for the three months and $2.58 million for the six months ended June 30, 2024.
• As of June 30, 2024, Tenax had cash and cash equivalents of $9.38 million.
• The company completed a private placement on August 8, 2024, raising gross proceeds of approximately $100 million.
• Tenax believes it has sufficient capital to fund its planned operations through the end of calendar year 2027.

Sentiment

Score: 7

Explanation: The document shows a mix of positive and negative aspects. The successful capital raise and progress in clinical trials are positive, but the continued losses and high R&D expenses are concerning. The overall sentiment is cautiously optimistic due to the funding and clinical progress.

Positives

• The company successfully raised approximately $100 million in gross proceeds through a private placement, significantly strengthening its financial position.
• Tenax has extended its cash runway to the end of 2027, providing financial stability for its clinical programs.
• The company is actively advancing its Phase 3 LEVEL trial for oral levosimendan and plans to initiate a second Phase 3 study in 2025.
• Tenax has secured patents for the use of levosimendan in PH-HFpEF, providing intellectual property protection.
• The company has global rights to oral and subcutaneous formulations of levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).

Negatives

• The company continues to incur significant net losses, with a net loss of $3.58 million for the three months ended June 30, 2024, and $7.37 million for the six months ended June 30, 2024.
• Research and development expenses have increased substantially, reflecting the high costs associated with clinical trials.
• The company has an accumulated deficit of approximately $304.6 million as of June 30, 2024.

Risks

• The company's future success is dependent on the successful outcome of its clinical trials, particularly the Phase 3 trials for levosimendan.
• There is a risk that the company may not be able to obtain regulatory approvals for its product candidates.
• The company may need to raise additional capital in the future, which could result in dilution for existing shareholders.
• The company faces competition from other pharmaceutical companies developing treatments for pulmonary hypertension.
• Delays in clinical trial enrollment or regulatory approvals could negatively impact the company's timeline and financial position.

Future Outlook

Tenax expects to use the proceeds from the recent private placement to complete its ongoing Phase 3 LEVEL trial, initiate a second Phase 3 trial, and for general corporate purposes. The company believes it has sufficient capital to fund operations through the end of calendar year 2027.

Management Comments

• Management believes the company has sufficient capital to fund its planned operations through the end of calendar year 2027.
• The company intends to use the net proceeds from the 2024 Private Placement to complete its ongoing Phase 3 LEVEL trial, to initiate all sites and advance enrollment in a second planned Phase 3 trial of oral levosimendan, and for working capital, capital expenditures, and other general corporate purposes.

Industry Context

Tenax is operating in the biopharmaceutical industry, specifically focusing on developing treatments for pulmonary hypertension. The company's focus on levosimendan for PH-HFpEF addresses a significant unmet medical need, as there are currently no approved therapies for this condition. The company's strategy of leveraging existing drugs with new formulations and clinical trial designs is a common approach in the industry to reduce development risk and time.

Comparison to Industry Standards

• Tenax's increased R&D spending is typical for a company in its stage of clinical development, as Phase 3 trials are generally the most expensive phase of drug development.
• The company's cash burn rate is consistent with other clinical-stage biopharmaceutical companies, but the recent capital raise provides a significant runway.
• The company's focus on repurposing existing drugs like levosimendan and imatinib is a strategy employed by many companies to reduce development risk and time.
• The company's intellectual property strategy, including patents for new uses of levosimendan, is a standard practice in the industry to protect its innovations.
• Compared to companies like United Therapeutics or Acceleron Pharma, which have approved therapies for pulmonary hypertension, Tenax is still in the clinical development phase, but the recent funding provides a pathway to potential commercialization.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for future growth.
• Employees will have job security and opportunities for professional development.
• Patients with PH-HFpEF may benefit from the development of new treatment options.
• Creditors will have increased confidence in the company's ability to meet its obligations.
• Suppliers will have opportunities to provide goods and services to the company.

Next Steps

• The company will continue to enroll patients in the Phase 3 LEVEL trial.
• Tenax plans to initiate a second Phase 3 study in 2025.
• The company will file a registration statement for the resale of shares issued in the recent private placement.
• Tenax will continue to monitor and analyze the results of its clinical trials.

Key Dates

Keywords

levosimendan, pulmonary hypertension, PH-HFpEF, clinical trial, Phase 3, imatinib, private placement, biopharmaceutical, research and development, FDA